Title: Reference 1 The FDA as a Public Health Agency
Title: Reference 2 Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies
Title: Reference 3 Renal Biomarker Qualification Submission: A Dialog Between the FDA-EMEA and Predictive Safety Testing Consortium
Availability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for Comments
Details Information
Attachments:
Reference 1 The FDA as a Public Health Agency
View Attachment:Reference 2 Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies
View Attachment:Reference 3 Renal Biomarker Qualification Submission: A Dialog Between the FDA-EMEA and Predictive Safety Testing Consortium
View Attachment:Comments
Related Documents